14/04/2019 00:02:21

Mondelēz Global LLC Conducts Voluntary Recall of Certain Chewy Chips Ahoy 13oz Due to Unexpected Solidified Ingredient in Product in the US

EAST HANOVER, N.J., April 13, 2019 (GLOBE NEWSWIRE) -- Mondelēz Global LLC announced today a limited voluntary recall in the United States of certain Chewy Chips Ahoy 13oz cookies. This voluntary recall is being conducted because of the potential for certain product to contain an unexpected solidified ingredient. Some reports of potential adverse health effects have been received. 

This recall is limited exclusively to the products listed in the table below, available at retail stores nationwide.  No other Chips Ahoy or Mondelēz Global LLC product is included in this recall.

Description

Retail UPC

Best When Used By Dates

 
 
CHIPS AHOY CHEWY COOKIE (13 OZ) 0 44000 03223 4

07SEP2019

08SEP2019

14SEP2019

15SEP2019

(Located on left top side of package by lift tab)

 

This recall is being conducted in the US.

Consumers who have this product should not eat it. Consumers can contact the company at 1-844-366-1171, 24 hours a day to get more information about the recall. Consumer Relations specialists are available Monday-Friday, 9am to 6pm EDT.

 

Contact:

 

Elisabeth Wenner

 

847-943-5678

 

news@mdlz.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d9cc2460-175c-4172-831b-df748b8f0e7c

Related content
13 Jun - 
Mondelēz International Invests $6 Million in Reading, U..
06 Jun - 
Mondelēz International to Present at Deutsche Bank Glob..
30 May - 
Mondelēz International Completes Sale of Cheese Busines..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
2
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
3
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
4
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
5
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting

Related stock quotes


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 June 2019 10:43:58
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB6 - 2019-06-16 11:43:58 - 2019-06-16 10:43:58 - 1000 - Website: OKAY